Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Aerovate Therapeutics Inc (NQ: AVTE )

2.700 +0.040 (+1.50%)
Streaming Delayed Price Updated: 12:04 PM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Aerovate Therapeutics Inc

AEROVATE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Aerovate Therapeutics, Inc. - AVTE
From Kahn Swick & Foti, LLC
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Air Transport Services Group, Inc. (Nasdaq– ATSG), Micropac Industries, Inc. (OTC - MPAD), Aerovate Therapeutics, Inc. (Nasdaq - AVTE), Outbrain Inc. (Nasdaq - OB)
From Brodsky & Smith LLC
Via GlobeNewswire
“The Future is Bright: Peraso Inc. (NASDAQ: PRSO) Expands Technology for Tactical Applications in High-Demand Industries – More Stocks Inside…”
Via AB Newswire
AVTE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Aerovate Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Shareholder Alert: Ademi LLP Investigates Whether Aerovate Therapeutics, Inc. Is Obtaining a Fair Price for Its Public Shareholders
From Ademi LLP
Via Business Wire
Aerovate Therapeutics and Jade Biosciences Announce Merger Agreement
From Jade Biosciences
Via GlobeNewswire
Aerovate Therapeutics to Explore Strategic Alternatives
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied doses 
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Baseline Data from the Phase 2b Portion of the IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present Patient Baseline Characteristics of the Phase 2b Portion of the Phase 2b/Phase 3 IMPAHCT Trial at the American Thoracic Society 2024 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2023 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Board of Directors Appoints Habib Dable as Board Chair
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Simultaneous Completion of Enrollment in Phase 2b Portion and Enrollment of First Patient into Phase 3 in the IMPAHCT Trial Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Third Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Second Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Appoints Habib Dable To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Jefferies Global Healthcare Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Nonclinical Pharmacokinetic Data in Support of AV-101, a Novel Dry Powder Inhaled Formulation of Imatinib, at the American Thoracic Society (ATS) 2023 International Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces First Quarter Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Full-Year 2022 Financial Results and Business Highlights
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics to Present at Cowen 43rd Annual Health Care Conference
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Appoints Donald Santel To Its Board of Directors
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Publishes Results of Phase 1 Study Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension in ERJ Open Research
Phase 1 results showed that AV-101 was generally well tolerated with significantly reduced systemic exposure compared to oral imatinib in healthy adult participants 
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Announces Third Quarter 2022 Financial Results
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Aerovate Therapeutics Presents Novel Phase 2b/Phase 3 IMPAHCT Trial Design at CHEST Annual Meeting 2022
Adaptive and efficient trial design may allow for expedited development timeline while maintaining scientific rigor 
From Aerovate Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.